Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study
C. Cripps(Canadian Partnership Against Cancer), E. A. Eisenhauer(Utrecht University), Gerald Batist(Jewish General Hospital), José Iglesias(Bionomics (Australia)), Jacques Jolivet(Hotel Dieu Hospital), Margot J. Burnell(Saint John Regional Hospital), B. Fisher(Ontario Institute for Cancer Research), W. Lofters(University of the West Indies System), Janet Dancey(Ontario Institute for Cancer Research)
Cited by 100
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k